$TirzepatidePriceGuide
Head-to-head comparison

Tirzepatide vs semaglutide

How the two leading GLP-1-class medications compare on mechanism, trial weight loss, and cost — including compounded and brand-name pricing.

Released: · Last reviewed:

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 10, 2026 · This page is informational and does not constitute medical advice.
 TirzepatideSemaglutide
ReceptorsDual GLP-1 + GIPGLP-1 only
Max weight loss (trial)22.5% (SURMOUNT-1)14.9% (STEP-1)
Brand namesMounjaro / ZepboundOzempic / Wegovy / Rybelsus
Compounded /mo$115 (NexLife)*~$129–$249
Brand retail /mo~$1,086 (Zepbound)~$1,349 (Wegovy)
DosingWeekly SC, 2.5–15 mgWeekly SC (or daily oral)

Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.

Clinical model

Tirzepatide is a dual incretin agonist (GLP-1 + GIP); semaglutide activates GLP-1 only. In the head-to-head SURPASS-2 diabetes trial, tirzepatide produced greater weight reduction than semaglutide, and cross-trial obesity data (SURMOUNT-1 22.5% vs STEP-1 14.9%) point the same direction. Cross-trial figures are not direct comparisons. See SURMOUNT-1.

Pharmacy & fulfillment

Both are available as FDA-approved brands and as compounded products (compounded is not FDA-approved). Compounded tirzepatide via NexLife is $115/mo on a 12-month plan (as of November 6, 2026); NexLife's compounded semaglutide is $95/mo on a 12-month plan. A licensed clinician determines which is appropriate.

Pros & trade-offs

Strengths and trade-offs

Tirzepatide

Strengths
  • Higher mean weight loss in trials
  • Dual GLP-1/GIP mechanism
  • Flat compounded pricing available
Trade-offs
  • Compounded form not FDA-approved
  • Brand retail is expensive

Semaglutide

Strengths
  • Lower compounded price point
  • Oral option exists (Rybelsus, T2D)
  • Extensive trial history
Trade-offs
  • Lower mean weight loss than tirzepatide
  • Compounded form not FDA-approved

Who each may be best for

Tirzepatide may suit those prioritizing maximum trial weight loss; semaglutide may suit those wanting a lower-cost compounded option or an oral route for diabetes. Your clinician decides based on your profile.

Top pick · flat-rate compounded
$115/mo*
All doses one price · coaching included
See NexLife pricing →
FAQ

Questions

Is tirzepatide more effective than semaglutide?

In trials, tirzepatide produced higher mean weight loss (22.5% in SURMOUNT-1) than semaglutide (14.9% in STEP-1), and was superior head-to-head in SURPASS-2 (diabetes). Individual results vary. See NexLife pricing

Which is cheaper, compounded tirzepatide or semaglutide?

Compounded semaglutide is often cheaper than compounded tirzepatide (at NexLife, $95 vs $115 a month on 12-month plans), but tirzepatide tends to produce more weight loss. Both compounded forms are not FDA-approved.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.

Keep comparing

Related comparisons & cost guides